Baseline patient characteristics, safety, and efficacy stratified per frailty status in patients receiving BsAbs for MM
| . | Frail group (N = 40) . | Nonfrail group (N = 62) . | P value . |
|---|---|---|---|
| Patient characteristics | |||
| Age, median (range), y | 78 (69-81) | 65 (59-70) | <.001 |
| Age ≥70 years, n (%) | 29 (73) | 18 (29) | <.001 |
| Male sex, n (%) | 16 (40) | 26 (42) | 1 |
| Race, non-Hispanic White, n (%) | 20 (50) | 30 (48) | 1 |
| ECOG PS ≥2, n (%) | 10 (36) | 0 | <.001 |
| CCI score, median (range) | 2 (1-3) | 1 (0-1) | <.001 |
| CrCl ≤60 mL/min, n (%) | 23 (62) | 13 (22) | <.001 |
| High-risk cytogenetics, n (%) | 20 (57) | 30 (55) | .98 |
| Prior lines of therapy, median (range) | 6 (4-7) | 5 (4-7) | .44 |
| Extramedullary disease, n (%) | 12 (36) | 17 (30) | .73 |
| Triple-class refractory disease, n (%) | 32 (80) | 42 (75) | .74 |
| Receiving teclistamab, n (%) | 32 (80) | 39 (63) | .11 |
| Prior anti-BCMA therapy, n (%) | 13 (33) | 20 (33) | 1 |
| Safety outcomes | |||
| CRS, any grade, n (%) | 23 (58) | 37 (60) | .99 |
| CRS, grade ≥3, n (%) | 0 | 2 (3) | .68 |
| ICANS, any grade, n (%) | 6 (15) | 5 (8) | .44 |
| ICANS, grade ≥3, n (%) | 1 (3) | 0 | .82 |
| Grade ≥3 cytopenia <30 days, n (%) | 16 (40) | 27 (44) | .83 |
| Grade ≥3 infection <90 days, n (%) | 11 (28) | 20 (32) | .77 |
| Length of hospital stay, median (range), d | 7 (7-8) | 7 (5-9) | .58 |
| TRM, n (%) | 5 (13) | 13 (21) | .27 |
| Causes of death, n (%) | |||
| All cause deaths | 8 (20) | 21 (34) | .13 |
| Disease progression | 3 (8) | 8 (13) | .39 |
| Infection | 3 (8) | 7 (11) | .53 |
| Other | 2 (5) | 6 (10) | .39 |
| Efficacy outcomes | |||
| Best ORR, n (%) | 32 (80) | 45 (73) | .40 |
| sCR/CR, n (%) | 6 (15) | 14 (23) | .35 |
| VGPR, n (%) | 19 (48) | 19 (31) | .086 |
| . | Frail group (N = 40) . | Nonfrail group (N = 62) . | P value . |
|---|---|---|---|
| Patient characteristics | |||
| Age, median (range), y | 78 (69-81) | 65 (59-70) | <.001 |
| Age ≥70 years, n (%) | 29 (73) | 18 (29) | <.001 |
| Male sex, n (%) | 16 (40) | 26 (42) | 1 |
| Race, non-Hispanic White, n (%) | 20 (50) | 30 (48) | 1 |
| ECOG PS ≥2, n (%) | 10 (36) | 0 | <.001 |
| CCI score, median (range) | 2 (1-3) | 1 (0-1) | <.001 |
| CrCl ≤60 mL/min, n (%) | 23 (62) | 13 (22) | <.001 |
| High-risk cytogenetics, n (%) | 20 (57) | 30 (55) | .98 |
| Prior lines of therapy, median (range) | 6 (4-7) | 5 (4-7) | .44 |
| Extramedullary disease, n (%) | 12 (36) | 17 (30) | .73 |
| Triple-class refractory disease, n (%) | 32 (80) | 42 (75) | .74 |
| Receiving teclistamab, n (%) | 32 (80) | 39 (63) | .11 |
| Prior anti-BCMA therapy, n (%) | 13 (33) | 20 (33) | 1 |
| Safety outcomes | |||
| CRS, any grade, n (%) | 23 (58) | 37 (60) | .99 |
| CRS, grade ≥3, n (%) | 0 | 2 (3) | .68 |
| ICANS, any grade, n (%) | 6 (15) | 5 (8) | .44 |
| ICANS, grade ≥3, n (%) | 1 (3) | 0 | .82 |
| Grade ≥3 cytopenia <30 days, n (%) | 16 (40) | 27 (44) | .83 |
| Grade ≥3 infection <90 days, n (%) | 11 (28) | 20 (32) | .77 |
| Length of hospital stay, median (range), d | 7 (7-8) | 7 (5-9) | .58 |
| TRM, n (%) | 5 (13) | 13 (21) | .27 |
| Causes of death, n (%) | |||
| All cause deaths | 8 (20) | 21 (34) | .13 |
| Disease progression | 3 (8) | 8 (13) | .39 |
| Infection | 3 (8) | 7 (11) | .53 |
| Other | 2 (5) | 6 (10) | .39 |
| Efficacy outcomes | |||
| Best ORR, n (%) | 32 (80) | 45 (73) | .40 |
| sCR/CR, n (%) | 6 (15) | 14 (23) | .35 |
| VGPR, n (%) | 19 (48) | 19 (31) | .086 |
Boldface indicates statistically significant values.
CrCl, creatinine clearance; ORR, overall response rate; sCR, stringent CR; VGPR, very good partial response.